Acknowledgment of Industry Collaboration
Overview
ONCO 2026 was designed to promote academic excellence and collaboration in oncology. Industry engagement supported the delivery of a comprehensive and impactful scientific program.
Industry Participation
A total of 28 industry partners contributed to ONCO 2026, representing a diverse range of the healthcare sector. These included pharmaceutical and biopharmaceutical companies, diagnostics and molecular pathology providers, medical technology and radiotherapy solution providers, medical device companies, and oncology support services.
Their participation reflected a shared commitment to advancing oncology education, innovation, and patient-centered cancer care.
Scientific Contribution
Industry collaboration played a key role in enabling knowledge exchange on emerging therapies, advanced diagnostics, and evolving technologies.
It also encouraged meaningful interaction between clinicians, researchers, and industry stakeholders, contributing to a deeper understanding of modern oncology practices.
Ethical Standards & Transparency
The Pakistan Society of Clinical Oncology (PSCO) remains committed to maintaining the highest standards of scientific integrity, transparency, and ethical collaboration.
All industry engagement during ONCO 2026 was conducted in accordance with established professional and ethical guidelines, ensuring that all educational content remained independent, evidence-based, and focused on patient benefit.
Acknowledgment
The Editorial Board of the Journal of Clinical Oncology Pakistan (JCOP) sincerely acknowledges and appreciates the contributions of all 28 industry partners.
Their responsible support significantly strengthened the academic, educational, and collaborative impact of ONCO 2026 and contributed to the advancement of oncology practice in Pakistan and the region.